AI Article Synopsis
- Cancer screening decisions often require patients to understand complex medical info quickly, which makes effective communication with unfamiliar primary care providers crucial for shared decision making (SDM).
- A new decision aid (DA) was tested on 20 patient-provider pairs, showing good acceptance and usability, with 80% of patients expressing intent to get screened for lung cancer and 85% of providers recommending it.
- Results suggest that a brief, easy-to-understand, and culturally sensitive DA can enhance the adoption of lung cancer screening guidelines, making shared decision-making more accessible in clinical settings.
Article Abstract
Background: Cancer screening-related decisions require patients to evaluate complex medical information in short time frames, often with primary care providers (PCPs) they do not know. PCPs play an essential role in facilitating comprehensive shared decision making (SDM).
Objective: To develop and test a decision aid (DA) and SDM strategy for PCPs and high-risk patients.
Design: The DA was tested with 20 dyads. Each dyad consisted of one PCP and one patient eligible for screening. A prospective, one-group, mixed-method study design measured fidelity, patient values, screening intention, acceptability and satisfaction.
Results: Four PCPs and 20 patients were recruited from an urban academic medical centre. Most patients were female (n = 14, 70%), most had completed high school (n = 15, 75%), and their average age was 65 years old. Half were African American. Patients and PCPs rated the DA as helpful, easy to read and use and acceptable in terms of time frame (observed t = 11.6 minutes, SD 2.7). Most patients (n = 16, 80%) indicated their intent to be screened. PCPs recommended screening for most patients (n = 17, 85%).
Conclusions: Evidence supports the value of lung cancer screening with LDCT for select high-risk patients. Guidelines endorse engaging patients and their PCPs in SDM discussions. Our findings suggest that using a brief, interactive, plain-language, culturally sensitive, theory-based DA and SDM strategy is feasible, acceptable and may be essential to effectively translate and sustain the adoption of LDCT screening recommendations into the clinic setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117480 | PMC |
| http://dx.doi.org/10.1111/hex.12675 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carbidopa and ZnCarbidopa Induce Reductive Stress in MDA-MB-231 Cells.
Chempluschem
December 2024
Centre for Inorganic Chemistry, Chemistry, Bv 120, e/ 60 y 64, Nº1465, 1900, La Plata, ARGENTINA.
The redox imbalance, caused by depletion or generation of reactive oxygen species (ROS), is a key mechanism by which metal complexes exert anticancer effects. Carbidopa has shown the ability to inhibit the MDA-MB-231 cell line, a highly aggressive triple-negative human breast adenocarcinoma, by inducing reductive stress. The metal complex of carbidopa with zinc (ZnCarbi) was designed to modify carbidopa's structure and exhibited increased cytotoxicity against MDA-MB-231 cells.
View Article and Find Full Text PDFImproving search strategies in bibliometric studies on machine learning in renal medicine.
Int Urol Nephrol
December 2024
Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan Province, China.
This paper evaluated the bibliometric study by Li et al. (Int Urol Nephrol, 2024) on machine learning in renal medicine. Although the study claims to summarize the forefront trends and hotspots in this field, several key issues require further clarification to effectively guide future research.
View Article and Find Full Text PDFRASGEF1C as a novel prognostic biomarker for LUAD.
Discov Oncol
December 2024
Department of Thoracic Surgery, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New Area, Shanghai, China.
Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood.
View Article and Find Full Text PDFExperience of individuals with lung and gastrointestinal cancers undergoing radiation therapy: a qualitative study.
Support Care Cancer
December 2024
Department of Oncology, University of Calgary, Calgary, Canada.
Purpose: Lung cancer remains one of the most diagnosed cancers in Canada and continues to be the leading cause of cancer deaths in Canada, responsible for 25% of all cancer deaths. Prior studies consistently report poor experiences of people with lung cancers. The study purpose was to explore the reasons for consistently poorer reported experience of people with lung cancer compared to people with gastrointestinal cancers, who previously have reported positive cancer care experiences within the same context, and to better understand key differences that influence patient experience.
View Article and Find Full Text PDFAn AI dose-influence matrix engine for robust pencil beam scanning protons therapy.
Med Phys
December 2024
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Background: Rapid planning is of tremendous value in proton pencil beam scanning (PBS) therapy in overcoming range uncertainty. However, the dose calculation of the dose influence matrix (D) in robust PBS plan optimization is time-consuming and requires substantial acceleration to enhance efficiency.
Purpose: To accelerate the D calculations in PBS therapy, we developed an AI-D engine integrated into our in-house treatment planning system (TPS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!